CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe

Table 4 Table showing contribution of each covariate on improving the model fit and percentage of inter-individual variability on EFV clearance accounted for

Covariate	Points decrease in OFV^a	DF^b	p-value	IIV explained (%)^c
CYP2B6*18	67.07	2	<0.0001	18.0
CYP2B6*6	36.03	2	<0.0001	16.4
Body weight	19.37	1	<0.0001	10.7
Sex	10.41	1	0.0013	9.9
Age	0.29000	1	0.590220	0.01
EFV-RIF interaction^d	1.93200	1	0.164540	1.1
CNS effect	1.01100	1	0.314660	0.14
CYP2A6*9	3.83600	1	0.050163	2.7
CYP 2A6*17	1.44	2	0.230140	1.8

^aChange in NONMEM objective function value. ^bDegrees of freedom. ^cInter- individual variability. ^dInteraction between efavirenz and rifampicin.

ISSN: 2050-6511